v3.26.1
Stockholders' Equity - Additional Information (Detail) - USD ($)
3 Months Ended 6 Months Ended
May 04, 2026
May 29, 2025
May 22, 2025
Nov. 27, 2024
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Mar. 31, 2026
Dec. 31, 2025
Dec. 31, 2024
Stockholders Equity Disclosure [Line Items]                      
Proceeds from the issuance of common stock               $ 23,000,000      
Aggregate amounts of restricted capital and statutory reserves             $ 131,600,000     $ 128,100,000  
Statutory reserve fund             10.00%        
Cumulative amount of statutory reserve fund             50.00%        
Appropriations to statutory reserve             $ 600,000 $ 0      
Common Stock                      
Stockholders Equity Disclosure [Line Items]                      
Shares outstanding         90,822,828 87,636,209 106,033,763 90,822,828 91,337,121 91,314,007 86,307,544
Issuance of Common Stock (in shares)         2,555,555 54,734          
Merger With Cullgen                      
Stockholders Equity Disclosure [Line Items]                      
Conversion of stock 10,023,615                    
Merger With Cullgen | Common Stock                      
Stockholders Equity Disclosure [Line Items]                      
Conversion of stock 14,450,527                    
Shares outstanding             0        
Redeemable Convertible Preferred Stock | Merger With Cullgen                      
Stockholders Equity Disclosure [Line Items]                      
Preferred stock, shares issued upon conversion 57,821,355                    
Shares outstanding             0        
Series B Preferred Stock (as Converted) | Merger With Cullgen                      
Stockholders Equity Disclosure [Line Items]                      
Conversion of stock 3,697,235                    
Gyre | Gyre Pharmaceuticals                      
Stockholders Equity Disclosure [Line Items]                      
Minority interest ownership indirectly holds             69.70%        
Cullgen                      
Stockholders Equity Disclosure [Line Items]                      
Minority interest ownership indirectly holds             61.50%        
2024 ATM Program                      
Stockholders Equity Disclosure [Line Items]                      
Proceeeds from issuance of aggregate gross sales       $ 50,000,000              
Percentage of commission for shares sold       3.00%              
Legal expenses incurred       $ 135,000              
Issuance of Common Stock (in shares)             0 54,734      
Proceeds from the issuance of common stock               $ 500,000      
Commissions and offering costs               $ 8,600,000      
May 2025 Underwritten Public Offering                      
Stockholders Equity Disclosure [Line Items]                      
Common stock issue and sold     2,222,222                
Public offering price     $ 9                
Underwriters option period     30 days                
Greenshoe Option                      
Stockholders Equity Disclosure [Line Items]                      
Common stock issue and sold     333,333                
Issuance of additional shares settled   333,333